A Special Interest Group (SIG) of the Peripheral Nerve SocietyMission
To improve the care and treatment of patients with inflammatory and immune-mediated neuropathies. This includes Guillain-Barré syndrome (GBS), chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), multifocal motor neuropathy (MMN), paraproteinemic demyelinating neuropathies (PDN), vasculitic neuropathies, and many other conditions. Learn more
Membership
Why Join the INC
By joining the INC, you will gain access to the leading international network of clinicians and scientists working in inflammatory neuropathy. You will receive emails sent only to INC members about relevant news and updates. You will be eligible to present your work at INC meetings and to stand for INC Board membership.
How to Join the INC
To join the INC, you must first join the PNS. There is no additional charge to join the INC. On the PNS online application form select INC from the list of special interest group(s) you wish to join. If you are already a PNS member, log in to your membership profile and update your SIGs to include INC.
INC Events
Bi-Monthly Virtual Grand Rounds
The INC organizes bi-monthly virtual grand rounds. As a member, you will receive emails to register for these events. View the Webinar calendar of events for details.
Research Studies
Investigator-led international research studies supported by the INC network.
Clinical Guidelines
The PNS has co-sponsored clinical guidelines for diagnosis and treatment of GBS, CIDP, MMN, paraproteinemic demyelinating neuropathies and non-systemic vasculitic neuropathy.
History & Past Meetings of the INC
History and previous meetings.
INC Board of Directors
The INC recognizes the need for:
- Better education of health care professionals to enable earlier diagnosis and treatment,
- More research into the pathogenesis of the inflammatory neuropathies,
- More trials of treatment for all forms of inflammatory neuropathy,
- More trials in children with inflammatory neuropathies,
- Improved outcome measures,
- Treatments for symptoms of particular concern to patients, such as fatigue and pain,
- A strategy for prioritizing and undertaking trials of candidate treatments efficiently, and
- Development and revision of inflammatory neuropathy guidelines.